
        <!DOCTYPE html>
        <html>
        <head>
            <title>Biogen Inc. (BIIB) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Biogen Inc. (BIIB)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">53</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">31</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">7</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.33</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=59e87c964602bcc8bccce301c15d9e6109a1550b0ffefc9f8e0a17563c32f3d9" target="_blank" rel="noopener noreferrer">FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.76
                                </span>
                            </div>
                            <div class="article-summary">Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that t...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8ac325eaebc6ca62bbd8cd12edd6a0b694688f2cd3f5b93dc6f505b44671057d" target="_blank" rel="noopener noreferrer">FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-29</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.87
                                </span>
                            </div>
                            <div class="article-summary">Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8bcdf440d667fc7d5cb8af92d9cbe31d149794a4057100d7b8d2c3eefea3710b" target="_blank" rel="noopener noreferrer">Leqembi Or Blarcamesine For Alzheimer's Disease: Which One Is Better</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-26</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Anavex's Blarcamesine shows promise vs. Leqembi with better safety and ease....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f589be1dc667f9be6687c7760da76c672078c070207881a906361c507bc6e319" target="_blank" rel="noopener noreferrer">Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.22
                                </span>
                            </div>
                            <div class="article-summary">TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=81db572aae98abda9363ac6d61315a28ef55390217c2a115a4c4a259a0b8824c" target="_blank" rel="noopener noreferrer">Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.55
                                </span>
                            </div>
                            <div class="article-summary">– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard a...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a72e52561a2dc76d1f2eb132bb71482ad08afdf273dec72b2af61c8dbc49d69a" target="_blank" rel="noopener noreferrer">Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">BEDFORD, Mass. & CAMBRIDGE, Mass., August 25, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with R...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f27c12d42fdcd7d18ca65a8c1ddf3f68baa4f282f4e98209e316c6f95a687efc" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Monday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-25</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Monday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9c17ae8c9528dd507c63d5fb6ccada559a31229c331d4acbe56b7596a5ce8027" target="_blank" rel="noopener noreferrer">Biogen Stock: Analyst Estimates & Ratings</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.48
                                </span>
                            </div>
                            <div class="article-summary">Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78" target="_blank" rel="noopener noreferrer">[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at a...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=de7cc61f7b72090da27c6cd7ed9b7dc24254cb04a039676a0ff2530bb367244a" target="_blank" rel="noopener noreferrer">Alzheimer's Disease: When All Else Fails</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-20</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Most candidates fail to show meaningful clinical benefit in Alzheimer's. Read why I am against investing in companies based solely on their Alzheimer's drug programs....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=10044eb56e5bac105636b96a9d8beaff526555f515821f6fdfc9c86d42fc33ab" target="_blank" rel="noopener noreferrer">2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.57
                                </span>
                            </div>
                            <div class="article-summary">While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competit...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5e1079b6f40e56f485ff1e228dafd1ac7bfd721de9162c10b2eca1ef1b7a20d7" target="_blank" rel="noopener noreferrer">eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=12ba64d8e1a5c399e8a26fde30baff11f534c2c2181e327272d8e72cdc183fa4" target="_blank" rel="noopener noreferrer">Biogen Inc. stock outperforms competitors on strong trading day</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-19</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock outperforms competitors on strong trading day...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b57b95b5e257a8ed46801de29067791825d1741aca966e61fe13f39ff05d5c56" target="_blank" rel="noopener noreferrer">[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approxima...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6973171bd0cf52d82f3f84b27d25a871dd5a8b2b7f2552aca2e361a691e8f8a8" target="_blank" rel="noopener noreferrer">5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was met with a positive market reaction. Management highlighted continued grow...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d3ed26fb2712d0634ee34cd1a3a8cd7f9a61df59c170fa5d10cadf71ccbb13df" target="_blank" rel="noopener noreferrer">BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above anal...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=322994fed4b380affd85d4b7193b9748e1030b15403e7ae7be9e65c46df69764" target="_blank" rel="noopener noreferrer">Scholar Rock Holding: Upcoming Milestone Approaches</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an analysis of SRRK stock now....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f748b6a3dc571de13eb1fedaabf19603761a479b602748cb464eeb611f0c9cde" target="_blank" rel="noopener noreferrer">Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-13</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.31
                                </span>
                            </div>
                            <div class="article-summary">A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Pr...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=84c3c8397fd408ef0ee389434f7fda91e32406726d3f0117d016d2c79c0aca64" target="_blank" rel="noopener noreferrer">First patient dosed in Phase III trial of zorevunersen for Dravet syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.49
                                </span>
                            </div>
                            <div class="article-summary">The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d1d4a3c8f36f6f1ad180dc4303d28b035a217c44f0c0db2f6f6857488a4abe18" target="_blank" rel="noopener noreferrer">New .med Domain Names Surpass 40,000 Pre-Orders in July</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.75
                                </span>
                            </div>
                            <div class="article-summary">With consumers struggling to differentiate between credible and unreliable medical information online, Medistry LLC's premium .med Top Level Domain (TLD) is poised to help....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=44898670113173f3eb11866417ec12fa9fc2e67d687993d71e9d0fda80d82bb4" target="_blank" rel="noopener noreferrer">Sector Update: Health Care Stocks Advance in Afternoon Trading</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9deb48a3b391d5a6975b76a8df57daff12c33f3652ba44ad11599bbf43d26ea9" target="_blank" rel="noopener noreferrer">Sector Update: Health Care Stocks Rise Late Afternoon</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-12</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index and the Healt...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7" target="_blank" rel="noopener noreferrer">Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.78
                                </span>
                            </div>
                            <div class="article-summary">While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d" target="_blank" rel="noopener noreferrer">Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.82
                                </span>
                            </div>
                            <div class="article-summary">While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=59d34aff570a51957d49ab370795dd4b8774689358da1f42bfc8b9809a1923ba" target="_blank" rel="noopener noreferrer">Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.46
                                </span>
                            </div>
                            <div class="article-summary">Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the chronic...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=afa82ba6bb4a5a3fbde9fb43fa9238cb6aef88050ffbdb8728ac0e7b55298cc0" target="_blank" rel="noopener noreferrer">Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.60
                                </span>
                            </div>
                            <div class="article-summary">BEDFORD, Mass., & CAMBRIDGE, Mass., August 11, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f4302736e134d312db861ee6a42413e3c15b1a6f3c006c01855f4df08bd69d95" target="_blank" rel="noopener noreferrer">Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.23
                                </span>
                            </div>
                            <div class="article-summary">– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refrac...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=534337382586b46f9ea2f8c1c5acc29450adc535e42615067428c75ff2a6bf7e" target="_blank" rel="noopener noreferrer">Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen (BIIB) and Stoke Therapeutics (STOK) said Monday they have dosed a first participant in a pha...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703" target="_blank" rel="noopener noreferrer">3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-11</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.80
                                </span>
                            </div>
                            <div class="article-summary">Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=57255d980f4da737750a4c15fff79c3d38b351ed8ad171479891927207455058" target="_blank" rel="noopener noreferrer">We Think Biogen's (NASDAQ:BIIB) Profit Is Only A Baseline For What They Can Achieve</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours Biogen......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6dde105958fe560ebdb5c8e3d41004d62882fe8e2a662ef3af62754c7884e26e" target="_blank" rel="noopener noreferrer">Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=808f5794e22062ad585b459a7278627950defff4d48397f82f8daf979de68d97" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Thursday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Thursday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=41d933ce123460804f2b1273cea3c1b557443880f5774debe087506fc6209ca0" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Wednesday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-06</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.91
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Wednesday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=02c4ed87efd185f9b4e51a47ad20af803a28f017f9ab4a07c8d8a2bbb3cc1991" target="_blank" rel="noopener noreferrer">Biogen Inc. (BIIB): A Bull Case Theory</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize the bulls’ thesis on BIIB. Biogen Inc.’s share was trading at $131.52 as o...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6652e78474b5c4bf59d987303e5ca8a2962d636cb97dc23ed02e63a29b4bd9b4" target="_blank" rel="noopener noreferrer">Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">SAN DIEGO, August 04, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott ...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ca1ca338388e431a12925359838a668c3b60c334427fd7044161c76aafdda6b7" target="_blank" rel="noopener noreferrer">Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-02</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment negative">
                                    -0.48
                                </span>
                            </div>
                            <div class="article-summary">Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f21d6b76388dc374b39417d55c8f119e1fd193d9ed2417f2a2a838ada6fdb9d6" target="_blank" rel="noopener noreferrer">Results: Biogen Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-02</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.92
                                </span>
                            </div>
                            <div class="article-summary">A week ago, Biogen Inc. ( NASDAQ:BIIB ) came out with a strong set of quarterly numbers that could potentially lead to......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=25dd9c096cf792ce59ec238cbdaeeeb67cc7cdb50ac4be25ccd60fd34d09568b" target="_blank" rel="noopener noreferrer">Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.44
                                </span>
                            </div>
                            <div class="article-summary">With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d6a8a126ed634ce3a96fcf1bec40ef58a0fa3c2ef4829016e253ba53f5122e04" target="_blank" rel="noopener noreferrer">Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.89
                                </span>
                            </div>
                            <div class="article-summary">The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b6ab9cbe247e43536b500d992a8c39b937fd7e4ee56077f59e321a55f231d03c" target="_blank" rel="noopener noreferrer">Regeneron cancer bispecific rejected again; Allogene discloses trial death</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.56
                                </span>
                            </div>
                            <div class="article-summary">The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=abcf80af83ca755a07b5846c255af1d8bdf93f5382842bb846c2c57dd4834969" target="_blank" rel="noopener noreferrer">Biogen Raises 2025 Outlook After Momentum in 1H</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment positive">
                                    0.79
                                </span>
                            </div>
                            <div class="article-summary">Biogen Raises 2025 Outlook After Momentum in 1H...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e" target="_blank" rel="noopener noreferrer">Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Discover key insights with the "Multiple Sclerosis - Global Clinical Trials Review, 2025" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=efee561e2b12f55c5ea0003229f3ded7909dc72f26be827225e719dc70e2e494" target="_blank" rel="noopener noreferrer">Biogen raises annual profit forecast on strong demand for rare disease drugs</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Its shares rose 5.4% in premarket trading, with the company also topping sales estimates for its keenly-watched Alzheimer's treatment Leqembi, which has struggled with slower uptake.  Meanwhile, Bioge...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7b75af14bdd466bdb24c0ca7b0b8fa2674a87e179f91673b3c2c0636537e71de" target="_blank" rel="noopener noreferrer">Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.56
                                </span>
                            </div>
                            <div class="article-summary">BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's sec...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f18520da70879589b802b7b5b1c42c6c48b98fa3a55d78a5a145c60a9a3ecb5b" target="_blank" rel="noopener noreferrer">Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.86
                                </span>
                            </div>
                            <div class="article-summary">Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance tha...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cab8c2b2225dd066a2724ffab3547f39f22d10971e9c172f6c823cf565185903" target="_blank" rel="noopener noreferrer">Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fe71c921775fd63ea133f96a126f6c8b99317eb4128d39ba458034a408f3ae03" target="_blank" rel="noopener noreferrer">Biogen (NASDAQ:BIIB) Reports Bullish Q2</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.83
                                </span>
                            </div>
                            <div class="article-summary">Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above anal...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=05b5a71e55451490848d9aa36c213672fea9bbed6dc0f871127939ee3814afc3" target="_blank" rel="noopener noreferrer">Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e732b152c6b10b4fca608183e877a8ad9b44b6899a22f56601054a16c2035684" target="_blank" rel="noopener noreferrer">Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=655744cf38e515c8955b7f1d7162e657e55d1e382984b71279a93c698c9353fb" target="_blank" rel="noopener noreferrer">Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=deaf8798f892727f0cec9d8041a6661e28cc2dfb096de433785d1a58134e2df4" target="_blank" rel="noopener noreferrer">Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsAlisha A....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a7bfda5b6979f20daad35b336b5ef8b78eec49065a494f0181eefef911334bc0" target="_blank" rel="noopener noreferrer">Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.95
                                </span>
                            </div>
                            <div class="article-summary">BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=eb61b4a4732c6fd2d642d2884db3f704a58df676a7d65f2d12a6d29ca88a053e" target="_blank" rel="noopener noreferrer">Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.33
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reporte...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        